FindTrial
Sign In

Open labelled, single arm, retrospective study of oral tofacitinib in vitiligo

A retrospective study to evaluate efficacy and safety of oral tofacitinib in vitiligo and its variants

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/01/048849
Enrollment
40
Registered
2023-01-10
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: Tofacitinib Tab: 5mg Twice a daily for 6 months Control Intervention1: NA: NA

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. All clinically diagnosed cases of different variants of vitiligo 2.Patients who were started on oral tofacitinib for vitiligo

Exclusion criteria

Exclusion criteria: •Patients receiving other systemic immunosuppressive drugs

Design outcomes

Primary

MeasureTime frame
To assess improvement in VASI from baselineTimepoint: After 6 months—

Secondary

MeasureTime frame
1.To assess number of patients achieving VASI 50/75/90 at the end of treatment follow-up period 2.To assess change in BSA (Body Surface Area) from baseline 3.To assess side effect profile of tofacitinib 4.To assess occurrence of new lesions during follow-up period 5.To assess time taken for halt in progression of lesions in different body sites 6.To assess time taken for start of re-pigmentation of lesions in different body sitesTimepoint: After 6 months—

Countries

India

Contacts

Public ContactDr Madura C

CUTIS Academy of Cutaneous Sciences

maduradr@gmail.com9632741998

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026